Balyasny Asset Management
XLO icon

Balyasny Asset Management’s Xilio Therapeutics XLO Stock Holding History

Balyasny Asset Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,204
Closed -$168K – 3621
2025
Q3 		$168K Hold
14,204
– – ﹤0.01% 2749
2025
Q2 		$135K Sell
14,204
-3,964
-22% -$41.9K ﹤0.01% 2659
2025
Q1 		$184K Sell
18,168
-6,348
-26% -$79.8K ﹤0.01% 2605
2024
Q4 		$328K Buy
24,516
+5,053
+26% +$69.5K ﹤0.01% 2350
2024
Q3 		$215K Hold
19,463
– – ﹤0.01% 2544
2024
Q2 		$258K Sell
19,463
-4,719
-20% -$73.9K ﹤0.01% 2270
2024
Q1 		$366K Buy
+24,182
New +$233K ﹤0.01% 2182

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Balyasny Asset Management's XLO Position: Q4 2025 in Review

Balyasny Asset Management sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 14,204 shares — an estimated $168K sold.

Balyasny Asset Management first reported a position in XLO in Q1 2024 and held it in 7 quarters. The position peaked at $366K in Q1 2024. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • Balyasny Asset Management reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 14,204 Xilio Therapeutics shares in Q4 2025, an estimated $168K.
  • Balyasny Asset Management first reported a position in Xilio Therapeutics in Q1 2024 and held it in 7 quarters.
  • Balyasny Asset Management's Xilio Therapeutics position peaked at $366K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.